Literature DB >> 9457451

Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment.

M Secrétan1, D Kuhn, G Soubrane, G Coscas.   

Abstract

UNLABELLED: This retrospective study was designed to help clarify the visual prognosis during long-term follow-up (5-10 years) of myopic choroidal neovascularization (CNV) with and without laser treatment in a referral population. PATIENTS AND METHODS: A group of 50 consecutive non-treated eyes and a group of 50 consecutive treated eyes were selected retrospectively. Inclusion criteria were: fluorescein angiographic documentation of CNV not involving the center of the fovea, visual acuity (VA) > or = 20/200, age less than 60, onset of symptoms < or = 6 months and at least five years of follow-up. The mean decrease in VA in non-treated and treated eyes during the follow-up was analysed on the basis of subgroups with the same initial VA.
RESULTS: Considering both groups (100 eyes) at presentation, 89% of CNV spared the center of the fovea but were located in the foveolar area (< 200 microns) and only 11% were extrafoveal (> or = 200 microns). In the natural history group, after five years all CNV involved the center of the fovea and mean VA was 20/160. In the treated group, at the end of the five year follow-up and after one or more laser session, 64% of eyes had a dry scar and mean VA was 20/74. Nevertheless there was a very high rate of recurrences (72%) and at the end of follow-up 36% of treated eyes had a subfoveal recurrence with a mean decrease in VA to 20/154. The difference between the mean decrease in VA of the treated and non-treated groups was statistically significant at two years. At five years (100 eyes), the difference persisted only for eyes with initial VA better than > or = 20/40 (P < 0.05). At eight years (76 eyes) and ten years (24 eyes), this difference was no longer significant. COMMENTS: This study confirms that CNV accompanying degenerative myopia has an extremely poor prognosis. Nevertheless analysis of final VA in both groups suggests that eyes with high initial VA gain more from treatment.

Entities:  

Mesh:

Year:  1997        PMID: 9457451     DOI: 10.1177/112067219700700401

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   1.922


  29 in total

1.  Visual outcomes for high myopic patients with or without myopic maculopathy: a 10 year follow up study.

Authors:  Y-F Shih; T-C Ho; C K Hsiao; L L-K Lin
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

Review 2.  Choroidal neovascularisation in pathological myopia: an update in management.

Authors:  W-M Chan; M Ohji; T Y Y Lai; D T L Liu; Y Tano; D S C Lam
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

3.  Transpupillary thermotherapy for myopic choroidal neovascularization: 1-year follow-up: TTT for myopic CNV.

Authors:  Sengul Ozdek; Ahmet Hondur; Gokhan Gurelik; Berati Hasanreisoglu
Journal:  Int Ophthalmol       Date:  2006-11-16       Impact factor: 2.031

4.  Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia.

Authors:  Ariko Kojima; Kyoko Ohno-Matsui; Satoshi Teramukai; Yoko Ishihara; Noriaki Shimada; Takeshi Yoshida; Yoshiharu Sugamoto; Takashi Tokoro; Manabu Mochizuki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-04-21       Impact factor: 3.117

5.  Epidemiology, treatment pattern and health care utilization of myopic choroidal neovascularization: a population based study.

Authors:  Ming-Chin Yang; Yen-Po Chen; Elise Chia-Hui Tan; Claudia Leteneux; Erin Chang; Carol Hy Chu; Chi-Chun Lai
Journal:  Jpn J Ophthalmol       Date:  2017-01-06       Impact factor: 2.447

6.  Sensitivity of fluorescein angiography alone or with SD-OCT for the diagnosis of myopic choroidal neovascularization.

Authors:  Paolo Milani; Amedeo Massacesi; Marco Setaccioli; Stefania Moschini; Elena Mantovani; Stefano Ciaccia; Fulvio Bergamini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-02-26       Impact factor: 3.117

7.  Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation in pathologic myopia.

Authors:  Faik Gelisken; Werner Inhoffen; Alexander Hermann; Salvatore Grisanti; Karl Ulrich Bartz-Schmidt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-07-17       Impact factor: 3.117

8.  Choroidal neovascularization following laser in situ keratomileusis for high myopia: a case series.

Authors:  Hui Yee Neo; Kumari Neelam; Chee Chew Yip; Hui Min Quah; Kah-Guan Au Eong
Journal:  Int Ophthalmol       Date:  2012-10-18       Impact factor: 2.031

9.  Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study.

Authors:  A Tufail; P J Patel; S Sivaprasad; W Amoaku; A C Browning; M Cole; R Gale; S George; A J Lotery; M Majid; M McKibbin; G Menon; Y Yang; C Andrews; C Brittain; A Osborne
Journal:  Eye (Lond)       Date:  2013-03-01       Impact factor: 3.775

10.  Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization.

Authors:  Lazaros Konstantinidis; Irmela Mantel; Jean-Antoine C Pournaras; Leonidas Zografos; Aude Ambresin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-29       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.